Advisory Council on Blood Stem Cell Transplantation; Notice of Meeting, 3913 [2011-1266]
Download as PDF
<![CDATA[
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 76, No. 14 / Friday, January 21, 2011 / Notices
should always check the Agency’s Web site
and call the appropriate advisory committee
hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: The committee will discuss
innovative approaches to the development of
drugs for orphan and rare diseases to support
decisions such as dose and trial design
selection. FDA will seek input and comment
on how to optimally utilize mechanistic
biomarkers and apply clinical pharmacology
tools, such as pharmacogenetics and
modeling and simulation, to facilitate
efficient and informative drug development
and regulatory review. FDA will present and
seek input from the committee on how
lessons learned from other applications of
clinical pharmacology tools in pediatrics and
oncology can be applied to orphan and rare
disease drugs. The committee will be asked
to comment on the current status and future
direction for clinical pharmacology studies
(e.g., dose-response, drug-drug interactions,
pharmacokinetics in patients with renal or
hepatic impairment) as they pertain to drug
development for orphan and rare diseases.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
February 15, 2011. Oral presentations from
the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
individuals interested in making formal oral
presentations should notify the contact
person and submit a brief statement of the
general nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and an
indication of the approximate time requested
to make their presentation on or before
February 7, 2011. Time allotted for each
presentation may be limited. If the number of
registrants requesting to speak is greater than
can be reasonably accommodated during the
scheduled open public hearing session, FDA
may conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 8, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Yvette
Waples, at least 7 days in advance of the
meeting.
VerDate Mar<15>2010
13:45 Jan 20, 2011
Jkt 223001
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for procedures
on public conduct during advisory
committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: January 18, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–1223 Filed 1–20–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Council on Blood Stem Cell
Transplantation; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: Advisory Council on Blood
Stem Cell Transplantation.
Date and Time: February 4, 2011,
from 3 p.m. to 5 p.m. EST.
ACTION: Notice of Advisory Council on
Blood Stem Cell Transplantation
(ACBSCT) Meeting to be Held by
Conference Call.
The ACBSCT will be
conducting a conference call to discuss:
(1) Final language of
recommendations from November 15,
2010, Council meeting; and
(2) Interim Report to Congress.
DATES: The conference call will be held
on February 4, 2011, at 3 p.m. to 5 p.m.
EST. Participants must dial: (800) 988–
9536 and enter the corresponding pass
code 2741198. Patricia A. Stroup, MBA,
MPA, is the call leader. Participants
should call no later than 2:50 p.m. EST
in order for the logistics to be set up.
Participants are asked to register for the
conference by contacting Passy Tongele
at (301) 443–0437 or e-mail
ptongele@hrsa.gov. The registration
deadline is February 2, 2011. The
Department will try to accommodate
those wishing to participate in the call.
Any member of the public can submit
written materials that will be distributed
to Council members prior to the
conference call. Parties wishing to
submit written comments should ensure
that the comments are received no later
than February 2, 2011, for
consideration. Comments should be
submitted to Passy Tongele, Healthcare
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
3913
Systems Bureau, HRSA, Parklawn
Building, Room 12C–06, 5600 Fishers
Lane, Rockville, Maryland 20857;
telephone (301) 443–0437; fax (301)
594–6095; or e-mail to
ptongele@hrsa.gov.
Members of the public can present
oral comments during the conference
call during the public comment period.
If a member of the public wishes to
speak, the Department should be
notified at the time the participant
registers. Others members of the public
will be allocated time if time permits.
FOR FURTHER INFORMATION CONTACT:
Patricia A. Stroup, MBA, MPA,
Executive Secretary, ACBSCT,
Healthcare Systems Bureau, HRSA,
Parklawn Building, Room 12C–06, 5600
Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–1127; fax
(301) 594–6095; or e-mail to
pstroup@hrsa.gov.
The
purpose of this call is to hear discussion
from the ACBSCT members on the final
language of the eight recommendations
approved at the November 15, 2010,
Council meeting and to discuss the
Interim Report to Congress. Public Law
111–264 states that ‘‘* * * the Secretary
of Health and Human Services * * * in
consultation with the Advisory Council
* * * shall submit to Congress an
interim report not later than 180 days
after the date of enactment of this Act
describing (A) the methods to distribute
Federal funds to cord blood banks used
at the time of submission of the report;
(B) how cord blood banks contract with
collection sites for the collection of cord
blood units; and (C) recommendations
for improving the methods to distribute
Federal funds described in
subparagraph (A) in order to encourage
the efficient collection of high-quality
and diverse cord blood units.’’
SUPPLEMENTARY INFORMATION:
Dated: January 14, 2011.
Robert Hendricks,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2011–1266 Filed 1–20–11; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDA. The
E:\FR\FM\21JAN1.SGM
21JAN1
]]>Agencies
[Federal Register Volume 76, Number 14 (Friday, January 21, 2011)]
[Notices]
[Page 3913]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1266]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Council on Blood Stem Cell Transplantation; Notice of
Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), notice is hereby given of the following
meeting:
Name: Advisory Council on Blood Stem Cell Transplantation.
Date and Time: February 4, 2011, from 3 p.m. to 5 p.m. EST.
ACTION: Notice of Advisory Council on Blood Stem Cell Transplantation
(ACBSCT) Meeting to be Held by Conference Call.
-----------------------------------------------------------------------
SUMMARY: The ACBSCT will be conducting a conference call to discuss:
(1) Final language of recommendations from November 15, 2010,
Council meeting; and
(2) Interim Report to Congress.
DATES: The conference call will be held on February 4, 2011, at 3 p.m.
to 5 p.m. EST. Participants must dial: (800) 988-9536 and enter the
corresponding pass code 2741198. Patricia A. Stroup, MBA, MPA, is the
call leader. Participants should call no later than 2:50 p.m. EST in
order for the logistics to be set up. Participants are asked to
register for the conference by contacting Passy Tongele at (301) 443-
0437 or e-mail ptongele@hrsa.gov. The registration deadline is February
2, 2011. The Department will try to accommodate those wishing to
participate in the call.
Any member of the public can submit written materials that will be
distributed to Council members prior to the conference call. Parties
wishing to submit written comments should ensure that the comments are
received no later than February 2, 2011, for consideration. Comments
should be submitted to Passy Tongele, Healthcare Systems Bureau, HRSA,
Parklawn Building, Room 12C-06, 5600 Fishers Lane, Rockville, Maryland
20857; telephone (301) 443-0437; fax (301) 594-6095; or e-mail to
ptongele@hrsa.gov.
Members of the public can present oral comments during the
conference call during the public comment period. If a member of the
public wishes to speak, the Department should be notified at the time
the participant registers. Others members of the public will be
allocated time if time permits.
FOR FURTHER INFORMATION CONTACT: Patricia A. Stroup, MBA, MPA,
Executive Secretary, ACBSCT, Healthcare Systems Bureau, HRSA, Parklawn
Building, Room 12C-06, 5600 Fishers Lane, Rockville, Maryland 20857;
telephone (301) 443-1127; fax (301) 594-6095; or e-mail to
pstroup@hrsa.gov.
SUPPLEMENTARY INFORMATION: The purpose of this call is to hear
discussion from the ACBSCT members on the final language of the eight
recommendations approved at the November 15, 2010, Council meeting and
to discuss the Interim Report to Congress. Public Law 111-264 states
that ``* * * the Secretary of Health and Human Services * * * in
consultation with the Advisory Council * * * shall submit to Congress
an interim report not later than 180 days after the date of enactment
of this Act describing (A) the methods to distribute Federal funds to
cord blood banks used at the time of submission of the report; (B) how
cord blood banks contract with collection sites for the collection of
cord blood units; and (C) recommendations for improving the methods to
distribute Federal funds described in subparagraph (A) in order to
encourage the efficient collection of high-quality and diverse cord
blood units.''
Dated: January 14, 2011.
Robert Hendricks,
Director, Division of Policy and Information Coordination.
[FR Doc. 2011-1266 Filed 1-20-11; 8:45 am]
BILLING CODE 4165-15-P
